ClinicalTrials.gg
CompletedNCT01033422Updated May 12, 2022Results posted

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

A Phase 2 interventional study of CF101 and Placebo for in Ocular Hypertension and Glaucoma, sponsored by Can-Fite BioPharma. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-12.

Primary conditionGlaucomaRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma
Why
  1. The study's listed conditions name Glaucoma, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma. Eligible patients with elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators, and will receive either CF101 pills or placebo (dummy) pills twice daily for 16 weeks. Ocular pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a regular basis.

Read the detailed description

This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of glaucoma or ocular hypertension.

This trial will be performed in 2 segments. In Segment 1, subjects will be randomized to receive either CF101 1.0 mg, or matching placebo, given orally every 12 hours for 16 weeks. Segment 1 will enroll approximately 44 subjects, randomized in a 3:1 ratio to CF101 1.0 mg or to placebo. At the conclusion of Segment 1, a Data Review Committee (DRC) will review safety and efficacy data and advise on progression of the trial to Segment 2. Segment 2 will enroll up to approximately 44 subjects randomized in a 3:1 ratio to CF101 2.0 mg 3:1 ratio to receive with CF101 2.0 mg, or matching placebo, given orally every 12 hours for 16 weeks.

At a Screening Visit (Visit 1, performed within 4 weeks prior to Baseline), subjects who provide written informed consent will have screening procedures performed, including complete medical, ophthalmologic, and medication histories; physical examination; vital signs and weight; electrocardiogram (ECG); ophthalmologic examination; tonometry; visual field (VF) assessment; corneal pachymetry; evaluation of inclusion and exclusion criteria; safety laboratory tests; serum pregnancy test for all females of child-bearing potential; and collection of concomitant medication information.

Subjects who successfully qualify will be randomized at Baseline (Visit 2) to their assigned medication (CF101 or matching placebo) to be taken orally every 12 hours for 16 weeks. Subjects will return for assessments and a new supply of study medication at Weeks 2, 4, 8, 12, and for final assessment and discharge at Week 16. A safety telephone call will be made at Week 18.

02

Conditions studied

  • Ocular Hypertension
  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • Ocular hypertension
  • Intraocular hypertension
03

In context

Glaucoma Reclassified

1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

This study's enrollment of 89 is above the median of 61 across 964 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Can-Fite BioPharma is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Compared within Glaucoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years of age and over;
  2. Ocular hypertension or open-angle glaucoma in at least 1 eye, diagnosed as any of the following:

    1. Untreated ocular hypertension without glaucomatous anatomic or VF changes; or
    2. Glaucoma diagnosed within the past 2 months but untreated;
    3. Previously treated glaucoma, provided that previous medication treatment has been inefficacious and/or intolerable, and has therefore been discontinued at least 3 weeks prior to Baseline; or
    4. Currently treated glaucoma with inadequate IOP control, meaning that IOP remains above target pressure as judged by the Investigator despite ≥3 weeks of treatment with a standard topical regimen (for guidance, the European Glaucoma Society defines "target pressure" as follows: "In most cases a peak IOP = 8 mm - 15 mmHg on a diurnal curve, or 30% IOP reduction from baseline");
  3. In subjects receiving a standard topical treatment regimen (per 2.d. above), the regimen and dose have not changed within 3 weeks of Screening, and are expected to remain stable throughout the treatment period;
  4. At both Screening and Baseline, IOP in at least 1 eye ("candidate" eye) is >21 mmHg at 0800-1000 hours and >21 mmHg in at least 1 measurement at least 3 hours following the first;
  5. Corneal thickness between 500 and 580 microns in both eyes;
  6. Corrected visual acuity +0.18 logMAR or better by Early Treatment Diabetic Retinopathy Study (ETDRS) methodology in the candidate eye (equivalent to 20/30);
  7. Females of must have a negative urine pregnancy test at screening and throughout the study, to be eligible for, and continue participation in, the study;
  8. Females of child-bearing potential must be willing to use 2 methods of deemed adequate by the Investigator (eg, oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;
  9. Ability to complete the study in compliance with the protocol; and
  10. Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  1. IOP >32 mmHg in either eye;
  2. History of angle-closure glaucoma;
  3. Anatomically narrow angles in either eye (ie, ≥75% of the circumference of the angle must be ≥Grade 2 by Shaffer criteria );
  4. In subjects with glaucoma, advanced VF defect in either eye, determined on reliable testing using the Humphrey Full-Threshold Algorithm for the Glaucoma Hemifield Test, defined as either:

    1. Mean deviation worse than -16 dB, or
    2. Threat to fixation (sensitivity 10 dB or worse affecting either or both test points closest to the point of fixation in the upper hemifield and at either or both the corresponding test points in the lower hemifield);
  5. In subjects with ocular hypertension, a score of >12 points on The Ocular Hypertension Treatment Study Group and European Glaucoma Prevention Study Group Primary Open-Angle Glaucoma Risk Table;
  6. Documented disc hemorrhage within the past 5 years in either eye;
  7. Secondary cause of IOP elevation;
  8. Glaucoma laser treatment in candidate eye within the past 3 months;
  9. ocular trauma to candidate eye within the past 6 months;
  10. Any major ocular surgery in the past, including keratorefractive surgery, in candidate eye, except for uncomplicated cataract surgery performed greater than 6 months prior to Screening;
  11. Astigmatism >3 diopters in either eye;
  12. Clinically significant acute or chronic ocular disease (eg, corneal edema, uveitis, severe keratoconjunctivitis sicca, active ocular infection, active herpes simplex keratitis, blepharitis, or acute conjunctivitis) that might interfere with the study;
  13. Concomitant contact lens use;
  14. Concomitant use of systemic medication that may affect IOP (eg, beta blockers, , calcium channel blockers, ACE inhibitors, or carbonic anhydrase inhibitors); however, systemic antihypertensive medications are allowed providing that the dose and regimen have been stable for at least 3 months prior to Screening and are expected to remain stable throughout the trial;
  15. Any abnormality preventing reliable applanation tonometry;
  16. Presence of uncontrolled asthma;
  17. Presence of uncontrolled arterial hypertension or symptomatic hypotension;
  18. Significant cardiac arrhythmia or conduction block, congestive heart failure ( Class 3-4), or any other evidence of clinically significant heart disease or clinically significant findings on screening ;
  19. level \<9.0 gm/L, at screening;
  20. count \<125,000/mm3, at screening;
  21. White blood cell count \<3500/mm3, at screening;
  22. Serum creatinine level greater than 1.5 times the laboratory's (ULN), at screening;
  23. Liver aminotransferase levels greater than 2 times the laboratory's ULN, at screening;
  24. Known or suspected immunodeficiency or positivity;
  25. Known infection with or C;
  26. Pregnancy, planned pregnancy, lactation, or inadequate as judged by the Investigator;
  27. Previous receipt of CF101;
  28. History of within the past 5 years (excluding basal cell carcinoma of the skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely excised);
  29. Active drug or alcohol dependence;
  30. Significant acute or chronic medical, ophthalmic, neurologic, or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
  31. Participation in another drug or vaccine trial concurrently or within 30 days; or
  32. Other conditions which would confound the study evaluations or endanger the safety of the subject.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    CF101 1mg

    CF101 1mg orally q12 hours

    Drug: CF101

  • Placebo comparator
    Placebo

    matching placebo orally q12 hours

    Drug: Placebo for

  • Experimental
    CF101 2mg

    CF101 2mg orally q12 hours

    Drug: CF101

Interventions

  • DrugCF101

    CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks

    Also known as: IB-MECA

  • DrugPlacebo for

    Matching placebo tablets orally every 12 hours for 16 weeks

    Also known as: Sugar pill

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure in mmHg

    The mean of the IOP measurements obtained at week 16

    Time frame: 16 weeks

Secondary outcomes

  1. Safety of CF 101

    To tabulate and enter the frequency (number) of adverse events during the treatment period of CF 101, by treatment arm.

    Time frame: 16 weeks

07

Results

Posted May 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneCF101 1mgCF101 2mgPlacebo
Started343223
Completed332822
Not completed141

Outcome measures

PrimaryIntraocular Pressure in mmHg

The mean of the IOP measurements obtained at week 16

Time frame:
16 weeks
Reported as:
Mean · Intraocular Pressure in mmHg
Intraocular Pressure in mmHg
Intraocular Pressure in mmHgCF101 1mgCF101 2mgPlacebo
Intraocular Pressure in mmHg19.01 ± 3.00119.84 ± 7.66218.95 ± 4.237
SecondarySafety of CF 101

To tabulate and enter the frequency (number) of adverse events during the treatment period of CF 101, by treatment arm.

Time frame:
16 weeks
Reported as:
Number · Number of events
Safety of CF 101
Number of eventsCF101 1mgCF101 2mgPlacebo
Safety of CF 10171110

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 1mg—1/34 (2.9%)4/34 (11.8%)
CF101 2mg—0/32 (0%)4/32 (12.5%)
Placebo—0/23 (0%)5/23 (21.7%)
Most frequent serious events
Most frequent serious events
EventCF101 1mgCF101 2mgPlacebo
HypertensionVascular disorders1/340/320/23
Most frequent other events
Most frequent other events
EventCF101 1mgCF101 2mgPlacebo
AnyInfections and infestations4/343/321/23
AnyEye disorders0/341/322/23
AnyGastrointestinal disorders0/341/322/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)CF101 1mgCF101 2mgPlaceboTotal
Mean61.08 ± 9.51355.51 ± 13.82756.26 ± 11.30356.83 ± 11.828
Sex: Female, Male
Sex: Female, Male(Participants)CF101 1mgCF101 2mgPlaceboTotal
Female25282073
Male94316
08

Study locations

3 sites
  • Specialized Hospital for Active Treatment for Eye Diseases "Zrenie"
    Sofia, 1408, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"
    Sofia, 1527, Bulgaria
  • Bnei Zion Medical Center
    Haifa, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2016 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2019, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2009
First posted
Dec 16, 2009
Start
Oct 2010
Primary completionActual
Dec 2016
CompletionActual
Apr 2017
Results first posted
May 23, 2019
Last update
May 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01033422
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Dec 16, 2009
Start date
Oct 2010
Primary completion
Dec 2016
Completion
Apr 2017
Results posted
May 23, 2019
Last update
May 12, 2022

Study contacts

Michael H Silverman, MD
study director · Can-Fite BioPharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion